Human Gastric Inhibitory Polypeptide Receptor (GIPR) ELISA Kit
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Human Gastric Inhibitory Polypeptide Receptor (GIPR) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Human Gastric inhibitory polypeptide receptor concentrations in tissue homogenates, cell lysates and other biological fluids.
Documents del producto
Product specifications
| Category | ELISA Kits |
| Immunogen Target | Gastric Inhibitory Polypeptide Receptor (GIPR) |
| Reactivity | Human |
| Detection Method | Colorimetric |
| Assay Data | Quantitative |
| Assay Type | Sandwich |
| Test Range | 0.312 ng/ml - 20 ng/ml |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Size 1 | 96 tests |
| Form | Lyophilized |
| Tested Applications | ELISA |
| Sample Type | Tissue homogenates, cell lysates and other biological fluids. |
| Availability | Shipped within 5-12 working days. The validity for this kit is 6 months. |
| Storage | Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual. |
| Dry Ice | No |
| UniProt ID | P48546 |
| Alias | PGQTL2,Gippr,GIP-R |
| Background | Elisa kits for GIPR |
| Status | RUO |
| Note | Validity: The validity for this kit is 6 months. This product is for research use only. The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments. Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein. |
Descripción
GIPR is a G-protein-coupled receptor expressed primarily on pancreatic β-cells, adipose tissue, intestinal cells, and the central nervous system, where it mediates the physiological actions of GIP Upon GIP binding, GIPR activates intracellular pathways including cAMP signaling, protein kinase A, and Epac2, leading to enhanced glucose-dependent insulin secretion from β-cells GIPR also regulates lipid metabolism in adipose tissue by increasing lipogenesis and triglyceride storage through lipoprotein lipase activation GIPR signaling in bone tissue promotes osteoblast activity and bone mineralization, supporting skeletal growth and homeostasis In the central nervous system, GIPR modulates energy balance and appetite through hypothalamic pathways Genetic variations in GIPR are linked to obesity, insulin resistance, and impaired glucose metabolism due to altered GIP signaling Pharmacological therapies targeting GIPR, including GIPR agonists and dual GIP/GLP-1 receptor agonists, are being developed to improve glucose control, reduce body weight, and treat components of metabolic syndrome
Related Products
Recombinant Human GIPR N-ECD
Ver Producto
Gastric Inhibitory Polypeptide Receptor (GIPR) Antibody
Rabbit polyclonal antibody against GIPR protein. Immunogen region is Internal.
Ver Producto
Gastric Inhibitory Polypeptide Receptor (GIPR) Antibody
GIPR also called glucose-dependent insulinotropic polypeptide, is a 42-amino acid polypeptide synthesized by K cells of the duodenum and small intestine. This protein was originally identified as an activity in gut extracts that inhibited gastric acid secretion and gastrin release, but subsequently was demonstrated to stimulate insulin release potently in the presence of elevated glucose. The insulinotropic effect on pancreatic islet beta-cells was then recognized to be the principal physiologic action of GIP. Together with glucagon-like peptide-1, GIP is largely responsible for the secretion of insulin after eating. The protein is involved in several other facets of the anabolic response.
Ver Producto